Flash FinanceUS
Market closed · weekend S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Edwards Lifesciences (EW)

Edwards Lifesciences: TAVR group president Larry Wood to resign effective September 1, 2025

Neutral Impact 3 of 5 leadership Written later

Edwards Lifesciences said Larry L. Wood, Corporate Vice President and Group President for Transcatheter Aortic Valve Replacement and Surgical Structural Heart, will resign effective September 1, 2025 to take a senior role at a company outside cardiovascular. Daniel J. Lippis, currently Corporate Vice President for Japan, Greater China and Asia Pacific, will take over as Corporate Vice President responsible for Transcatheter Aortic Valve Replacement on the same date.

Key points

  • Larry L. Wood notified the board on July 21, 2025 of his resignation
  • Resignation takes effect September 1, 2025
  • Daniel J. Lippis will assume responsibility for Transcatheter Aortic Valve Replacement
  • The filing does not disclose a replacement for Lippis's Japan, Greater China and Asia Pacific role

The filing

CompanyEdwards Lifesciences (EW)
Form8-K, current report
Filed with the SECJul 24, 2025, 6:22 PM ET
Accession number0001193125-25-164527

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 1:42 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on July 24, 2025.

Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.